Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Research Article

COVID Tarnish Lung: Residual Radiological Lung Consequences of Infection with COVID-19

Author(s): Ahmed Mohammed Abumossalam*, Taha Taha Abdelgawad, Mohamad Abomesllam Ibrahim, Mohamad Darwish Mohamad, Dalia Abdelsattar Ahmed and Hanan Abdelsattar Elhalaby

Volume 18, Issue 2, 2022

Published on: 14 March, 2022

Page: [121 - 133] Pages: 13

DOI: 10.2174/1573398X18666220218101742

Price: $65

Abstract

Background: COVID-19 has still been expressed as a mysterious viral infection with dramatic pulmonary consequences.

Objectives: This article aims to study the radiological pulmonary consequences of respiratory covid-19 infection at 6 months and their relevance to the clinical stage, laboratory markers, and management modalities.

Methods: This study was implemented on two hundred and fifty (250) confirmed positive cases for COVID-19 infections. One hundred and ninety-seven cases (197) who completed the study displayed residual radiological lung shadowing (RRLS) on follow-up computed tomography (CT) of the chest. They were categorized by Simple clinical classification of COVID-19 into groups A, B and C.

Results: GGO, as well as reticulations, were statistically significantly higher in group A than the other two groups; however, bronchiectasis changes, parenchymal scarring, nodules as well as pleural tractions were statistically significantly higher in group C than the other two groups.

Conclusion: Respiratory covid-19 infection might be linked to residual radiological lung shadowing. Ground glass opacities GGO, reticulations pervaded in mild involvement with lower inflammatory markers level, unlike, severe changes that expressed scarring, nodules and bronchiectasis changes accompanied by increased levels of inflammatory markers.

Keywords: COVID-19, residual radiological shadowing, respiratory support, invasive mechanical ventilation-GGO, reticulations, scarring, nodule.

Graphical Abstract
[1]
Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus dis-ease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55(3): 105924.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105924] [PMID: 32081636]
[2]
Mackenzie JS, Smith DW. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don’t. Microbiol Aust 2020; 41(1): MA20013.
[http://dx.doi.org/10.1071/MA20013] [PMID: 32226946]
[3]
Adams HJA, Kwee TC, Yakar D, Hope MD, Kwee RM. Chest CT imaging signature of coronavirus disease 2019 infection: In pursuit of the scientific evidence. Chest 2020; 158(5): 1885-95.
[http://dx.doi.org/10.1016/j.chest.2020.06.025] [PMID: 32592709]
[4]
Maveddat A, Mallah H, Rao S, Ali K, Sherali S, Nugent K. Severe acute respiratory distress syndrome secondary to coronavirus 2 (SARS-CoV-2). Int J Occup Environ Med 2020; 11(4): 157-78.
[http://dx.doi.org/10.34172/ijoem.2020.2202] [PMID: 33098401]
[5]
Gezer NS, Ergan B, Barış MM, et al. COVID-19 S: A new proposal for diagnosis and structured reporting of COVID-19 on computed tomography imaging. Diagn Interv Radiol 2020; 26(4): 315-22.
[http://dx.doi.org/10.5152/dir.2020.20351] [PMID: 32558646]
[6]
Capaccione KM, Leb JS, D’souza B, Utukuri P, Salvatore MM. Acute myocardial infarction secondary to COVID-19 infection: A case report and review of the literature. Clin Imaging 2021; 72: 178-82.
[http://dx.doi.org/10.1016/j.clinimag.2020.11.030] [PMID: 33296828]
[7]
Gülsen A. Simple classification of COVID-19 patients. J Lung Pulm Respir Res 2020; 7(3): 62-3.
[http://dx.doi.org/10.15406/jlprr.2020.07.00230]
[8]
Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from non-COVID-19 viral pneumonia at chest CT. Radiology 2020; 296(2): E46-54.
[http://dx.doi.org/10.1148/radiol.2020200823] [PMID: 32155105]
[9]
Xu Y-H, Dong J-H, An W-M, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect 2020; 80(4): 394-400.
[http://dx.doi.org/10.1016/j.jinf.2020.02.017] [PMID: 32109443]
[10]
Han X, Cao Y, Jiang N, et al. Novel coronavirus disease 2019 (COVID-19) pneumonia progression course in 17 discharged patients: Comparison of clinical and thin-section computed tomography features during recovery. Clin Infect Dis 2020; 71(15): 723-31.
[http://dx.doi.org/10.1093/cid/ciaa271] [PMID: 32227091]
[11]
Fatima S, Ratnani I, Husain M, Surani S. Radiological findings in patients with COVID-19. Cureus 2020; 12(4): e7651.
[PMID: 32411552]
[12]
Chang Y-C, Yu C-J, Chang S-C, et al. Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology 2005; 236(3): 1067-75.
[http://dx.doi.org/10.1148/radiol.2363040958] [PMID: 16055695]
[13]
Prokop M, van Everdingen W, van Rees Vellinga T, et al. CO-RADS: A categorical CT assessment scheme for patients suspected of hav-ing COVID-19 definition and evaluation. Radiology 2020; 296(2): E97-E104.
[http://dx.doi.org/10.1148/radiol.2020201473] [PMID: 32339082]
[14]
Han X, Fan Y, Alwalid O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021; 299(1): E177-86.
[http://dx.doi.org/10.1148/radiol.2021203153] [PMID: 33497317]
[15]
Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 β and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995; 107(4): 1062-73.
[http://dx.doi.org/10.1378/chest.107.4.1062] [PMID: 7705118]
[16]
Desai SR, Wells AU, Rubens MB, Evans TW, Hansell DM. Acute respiratory distress syndrome: CT abnormalities at long-term follow-up. Radiology 1999; 210(1): 29-35.
[http://dx.doi.org/10.1148/radiology.210.1.r99ja2629] [PMID: 9885583]
[17]
George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 2020; 8(8): 807-15.
[http://dx.doi.org/10.1016/S2213-2600(20)30225-3] [PMID: 32422178]
[18]
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med 2020; 46(6): 1089-98.
[http://dx.doi.org/10.1007/s00134-020-06062-x] [PMID: 32367170]
[19]
Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: The Berlin Definition. JAMA 2012; 307(23): 2526-33.
[PMID: 22797452]
[20]
Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169(4): 977-83.
[http://dx.doi.org/10.2214/ajr.169.4.9308447] [PMID: 9308447]
[21]
Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020; 30(12): 6808-17.
[http://dx.doi.org/10.1007/s00330-020-07033-y] [PMID: 32623505]
[22]
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
[http://dx.doi.org/10.1016/S2213-2600(20)30076-X] [PMID: 32085846]
[23]
Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 2020; 92(5): 491-4.
[http://dx.doi.org/10.1002/jmv.25709] [PMID: 32056249]
[24]
Oudkerk M, Büller HR, Kuijpers D, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. Radiology 2020; 297(1): E216-22.
[http://dx.doi.org/10.1148/radiol.2020201629] [PMID: 32324101]
[25]
Thoma P, Rondelet B, Mélot C, Tack D, Naeije R, Gevenois PA. Acute pulmonary embolism: relationships between ground-glass opacifi-cation at thin-section CT and hemodynamics in pigs. Radiology 2009; 250(3): 721-9.
[http://dx.doi.org/10.1148/radiol.2503081134] [PMID: 19164124]
[26]
Wu X, Kim GH, Salisbury ML, et al. Computed tomographic biomarkers in idiopathic pulmonary fibrosis. The future of quantitative anal-ysis. Am J Respir Crit Care Med 2019; 199(1): 12-21.
[http://dx.doi.org/10.1164/rccm.201803-0444PP] [PMID: 29986154]
[27]
Piao Z, Han SJ, Cho HJ, Kang MW. Feasibility of electromagnetic navigation bronchoscopy-guided lung resection for pulmonary ground-glass opacity nodules. J Thorac Dis 2020; 12(5): 2467-73.
[http://dx.doi.org/10.21037/jtd.2020.03.71] [PMID: 32642153]
[28]
Nie L, Dai K, Wu J, et al. Clinical characteristics and risk factors for in-hospital mortality of lung cancer patients with COVID-19: A multi-center, retrospective, cohort study. Thorac Cancer 2021; 12(1): 57-65.
[http://dx.doi.org/10.1111/1759-7714.13710] [PMID: 33142039]
[29]
Migliore M. Ground glass opacities of the lung before, during and post COVID-19 pandemic. Ann Transl Med 2021; 9(13): 1042.
[http://dx.doi.org/10.21037/atm-21-2095] [PMID: 34422954]
[30]
Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2021; 2(1): e13-22.
[http://dx.doi.org/10.1016/S2666-5247(20)30172-5] [PMID: 33521734]
[31]
Wilkinson T, Dixon R, Page C, et al. Accord: A multicentre, seamless, Phase 2 adaptive randomisation platform study to assess the effica-cy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: A structured summary of a study proto-col for a randomised controlled trial. Trials 2020; 21(1): 691.
[http://dx.doi.org/10.1186/s13063-020-04584-9] [PMID: 32736596]
[32]
Mehta P, Porter JC, Manson JJ, et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med 2020; 8(8): 822-30.
[http://dx.doi.org/10.1016/S2213-2600(20)30267-8] [PMID: 32559419]
[33]
Mathioudakis AG, Fally M, Hashad R, Knight S, Felton T, Vestbo J. COVID-19 clinical trials: Unraveling a methodological gordian knot. Am J Respir Crit Care Med 2020; 202(5): 635-7.
[http://dx.doi.org/10.1164/rccm.202005-1942ED] [PMID: 32634026]
[34]
Thomson K, Nachlis H. Emergency use authorizations during the COVID-19 pandemic: Lessons from hydroxychloroquine for vaccine authorization and approval. JAMA 2020; 324(13): 1282-3.
[http://dx.doi.org/10.1001/jama.2020.16253] [PMID: 32870235]
[35]
Maor Y, Cohen D, Paran N, et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. EClinicalMedicine 2020; 26: 100525.
[http://dx.doi.org/10.1016/j.eclinm.2020.100525] [PMID: 32923991]
[36]
Paumgartten FJR, Oliveira ACAX. Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Cien Saude Colet 2020; 25(9): 3413-9.
[http://dx.doi.org/10.1590/1413-81232020259.16792020] [PMID: 32876249]
[37]
Mostafa AS, Abdalbaky A, Fouda E, Shaaban HH, Elnady HG, Hassab-Allah M. Practical approach to COVID-19: An Egyptian pediatric consensus. Egyptian Pediatric Association Gazette 2020; 68(1): 1-8.
[http://dx.doi.org/10.1186/s43054-020-00037-9]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy